Target Price | €241.36 |
Price | €189.50 |
Potential |
27.37%
register free of charge
|
Number of Estimates | 14 |
14 Analysts have issued a price target Sartorius Stedim Biotech 2026 .
The average Sartorius Stedim Biotech target price is €241.36.
This is
27.37%
register free of charge
€251.00
32.45%
register free of charge
€220.00
16.09%
register free of charge
|
|
A rating was issued by 16 analysts: 11 Analysts recommend Sartorius Stedim Biotech to buy, 5 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Sartorius Stedim Biotech stock has an average upside potential 2026 of
27.37%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Billion € | 2.78 | 3.01 |
0.16% | 8.10% | |
EBITDA Margin | 25.16% | 29.99% |
1.36% | 19.21% | |
Net Margin | 6.30% | 11.54% |
43.55% | 83.22% |
13 Analysts have issued a sales forecast Sartorius Stedim Biotech 2025 . The average Sartorius Stedim Biotech sales estimate is
This results in the following potential growth metrics:
13 Analysts have issued an Sartorius Stedim Biotech EBITDA forecast 2025. The average Sartorius Stedim Biotech EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
11 Sartorius Stedim Biotech Analysts have issued a net profit forecast 2025. The average Sartorius Stedim Biotech net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share € | 1.81 | 3.56 |
46.13% | 96.69% | |
P/E | 53.19 | |
EV/Sales | 7.02 |
11 Analysts have issued a Sartorius Stedim Biotech forecast for earnings per share. The average Sartorius Stedim Biotech EPS is
This results in the following potential growth metrics and future valuations:
Sartorius Stedim Biotech...
Analyst | Rating | Action | Date |
---|---|---|---|
ESN/CIC MARKET SOLUTIONS |
Locked
➜
Locked
|
Locked | Apr 02 2025 |
HSBC |
Locked
➜
Locked
|
Locked | Mar 23 2025 |
NEPHRON RESEARCH |
Locked
➜
Locked
|
Locked | Jan 30 2025 |
JEFFERIES |
Locked
➜
Locked
|
Locked | Jan 29 2025 |
ODDO BHF |
Locked
➜
Locked
|
Locked | Jan 27 2025 |
HSBC |
Locked
➜
Locked
|
Locked | Nov 24 2024 |
BERENBERG |
Locked
➜
Locked
|
Locked | Nov 18 2024 |
Analyst Rating | Date |
---|---|
Locked
ESN/CIC MARKET SOLUTIONS:
Locked
➜
Locked
|
Apr 02 2025 |
Locked
HSBC:
Locked
➜
Locked
|
Mar 23 2025 |
Locked
NEPHRON RESEARCH:
Locked
➜
Locked
|
Jan 30 2025 |
Locked
JEFFERIES:
Locked
➜
Locked
|
Jan 29 2025 |
Locked
ODDO BHF:
Locked
➜
Locked
|
Jan 27 2025 |
Locked
HSBC:
Locked
➜
Locked
|
Nov 24 2024 |
Locked
BERENBERG:
Locked
➜
Locked
|
Nov 18 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.